2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Head & Neck
1
Breast
1
Conditions
Breast Neoplasms
275
Carcinoma, Intraductal, Noninfiltrating
25
Breast Carcinoma In Situ
21
Neoplasm Metastasis
14
Neoplasms
13
Breast Neoplasms, Male
12
Ovarian Neoplasms
10
Inflammatory Breast Neoplasms
7
Glioblastoma
6
Endometrial Neoplasms
6
Prostatic Neoplasms
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Fallopian Tube Neoplasms
4
Breast Cancer Female
4
Brain Neoplasms
4
Recurrence
3
Obesity
3
Hot Flashes
3
Glioma
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Ductal, Breast
3
Breast Diseases
3
Astrocytoma
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sleep Wake Disorders
2
Sarcoma
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Interventions
Cisplatin
182
Radiotherapy
81
Paclitaxel
80
Brachytherapy
74
Carboplatin
72
pembrolizumab
63
Bevacizumab
40
Surveys and Questionnaires
29
Colposcopy
29
Radiation
28
Gemcitabine
28
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
27
Topotecan
26
Magnetic Resonance Spectroscopy
24
Blood Specimen Collection
23
human papillomavirus vaccine, L1 type 16, 18
22
Nivolumab
22
Drug Therapy
22
Papillomavirus Vaccines
20
atezolizumab
19
Platinum
19
Radiotherapy, Intensity-Modulated
18
Biopsy
18
Docetaxel
17
Taxes
16
Cyclophosphamide
16
Early Intervention, Educational
15
1,2-diaminocyclohexaneplatinum II citrate
15
Methods
14
fludarabine
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Tamoxifen
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT02482740
2015-06-26
TGOG1005
Buddhist Tzu Chi General Hospital
Phase 2
Unknown
44 enrolled